Aprea Therapeutics, Inc.

Aprea Therapeutics, Inc.

APRE · Nasdaq

Aprea Therapeutics, Inc. (APRE) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Aprea Therapeutics, Inc. in 2026. The next earnings report is expected on November 5, 2026.

Earnings calendar

Next earnings date

05 Nov 2026

In 78 days

EPS estimate

-0.19

Revenue estimate

307.5K

Past earnings

12 Aug 2026
EPS actual
-0.07 (+60.6%)
estimate -0.18
Revenue actual
253.0K (0.0%)
estimate 253.0K
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
13 May 2026
EPS actual
-0.22 (-3.5%)
estimate -0.21
Revenue actual
281.0K
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
16 Mar 2026
EPS actual
-0.32 (+17.9%)
estimate -0.39
Revenue actual
3.3K
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
12 Nov 2025
EPS actual
-0.47 (-38.2%)
estimate -0.34
Revenue actual
1.8K
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

Aprea Therapeutics beat consensus estimates in its latest earnings report, with EPS of $-0.07 versus an estimate of $-0.1775 and revenue of $253 thousand that met expectations exactly, showing a 0.0% variance. In the prior quarter EPS missed expectations while revenue came in ahead of estimates.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
Nasdaq
CEO
Oren Gilad
Employees
8
IPO date
03 Oct 2019
ISIN
US03836J2015
Website
atrinpharma.com

Frequently asked questions

When does Aprea Therapeutics, Inc. (APRE) next report earnings?

Aprea Therapeutics, Inc. (APRE) is scheduled to report earnings on November 5, 2026.

What was Aprea Therapeutics, Inc.'s most recent earnings date?

Aprea Therapeutics, Inc. (APRE) last reported earnings on August 12, 2026.

Where is Aprea Therapeutics, Inc. stock listed?

Aprea Therapeutics, Inc. (APRE) is listed on Nasdaq.